Scholarlink

Background <p>Postoperative opioid use for pain management in breast reconstruction can lead to significant side effects. Enhanced Recovery After Surgery (ERAS) protocols, including regional anesthetic blocks, aim to reduce opioid consumption. Exparel, a liposomal bupivacaine, offers prolonged pain relief compared to traditional Marcaine.</p> Methods <p>A retrospective study was conducted on 163 patients who underwent breast reconstruction from January 2019 to June 2022. Patients received either Marcaine or Exparel as part of their regional anesthesia. Opioid prescriptions were tracked and converted to morphine equivalent doses (MED).</p> Results <p>Patients who received Exparel consumed significantly fewer opioids (97.21 ± 81.77 MED) compared to those who received Marcaine (160.53 ± 150.58 MED). The Exparel group also had fewer total opioid prescriptions (1.35 vs. 1.90). No significant differences were found based on breast reconstruction type.</p> Conclusion <p>Exparel significantly reduces postoperative opioid use compared to Marcaine in breast reconstruction, potentially improving recovery and reducing opioid-related risks.</p> Level of Evidence III <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors <a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Does Liposomal Bupivacaine Reduce Postoperative Opioid Use in Tissue Expander Based Breast Reconstruction?

  • 期刊论文

  • 发表日期：

    2025年12月20日

查看全文
  • Thomas Ren,
  • Andre Galenchik-Chan,
  • Nicolas Oltean,
  • Isabelle Van Roy,
  • Eric Forney,
  • Tomasso Addona

摘要

Background

Postoperative opioid use for pain management in breast reconstruction can lead to significant side effects. Enhanced Recovery After Surgery (ERAS) protocols, including regional anesthetic blocks, aim to reduce opioid consumption. Exparel, a liposomal bupivacaine, offers prolonged pain relief compared to traditional Marcaine.

Methods

A retrospective study was conducted on 163 patients who underwent breast reconstruction from January 2019 to June 2022. Patients received either Marcaine or Exparel as part of their regional anesthesia. Opioid prescriptions were tracked and converted to morphine equivalent doses (MED).

Results

Patients who received Exparel consumed significantly fewer opioids (97.21 ± 81.77 MED) compared to those who received Marcaine (160.53 ± 150.58 MED). The Exparel group also had fewer total opioid prescriptions (1.35 vs. 1.90). No significant differences were found based on breast reconstruction type.

Conclusion

Exparel significantly reduces postoperative opioid use compared to Marcaine in breast reconstruction, potentially improving recovery and reducing opioid-related risks.

Level of Evidence III

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.